Tesamorelin is a synthetic analogue of the 44-amino-acid form of growth hormone-releasing factor, GRF(1-44). It has been the subject of extensive pharmaceutical development and is one of the more analytically complex peptides in the research-supply landscape due to its size and its N-terminal chemical modification.
What Tesamorelin is
Tesamorelin is a chemically synthesised 44-residue peptide corresponding to the sequence of human growth hormone-releasing factor GRF(1-44), modified by the addition of an N-terminal trans-3-hexenoyl (a small unsaturated fatty-acid) group. The N-terminal acyl modification substantially reduces enzymatic degradation of the peptide by dipeptidyl peptidase IV (DPP-IV), giving it a longer plasma half-life than the unmodified parent sequence.
Molecular information
- Origin: Synthetic analogue of the 44-residue GRF(1-44) sequence
- N-terminal modification: trans-3-hexenoyl group
- Number of residues: 44 (in the peptide chain)
- Approximate monoisotopic mass: ~5196 Da for the modified peptide (the exact value depends on precise sequence conventions and any salt/counter-ion contribution)
- Physical form: Typically supplied as a white lyophilised powder, often as an acetate salt
At 44 residues plus an N-terminal fatty-acid modification, Tesamorelin is analytically more complex than the shorter research peptides in this profile series. Its size and modification place it firmly in the domain of high-resolution mass spectrometry for reliable identity confirmation.
Areas of published research
Tesamorelin has been developed as a synthetic GRF analogue with pharmaceutical intent, and its research literature is substantial:
- Growth hormone axis research — as a stable GRF(1-44) analogue, Tesamorelin is a research tool for probing the pulsatile secretion of growth hormone from the anterior pituitary and downstream IGF-1 responses.
- Peptide stability research — the effect of the N-terminal trans-3-hexenoyl modification on peptide stability and DPP-IV resistance has been characterised in the literature.
- Body-composition research — the peptide has been studied in the context of changes in body composition in clinical trial settings, in the specific clinical population for which it is regulated in some jurisdictions. This body of literature is clinical, not preclinical, and is beyond the scope of a research-supply profile.
Research history and regulatory context
Tesamorelin has undergone formal pharmaceutical development and is registered as a prescription medicine in some jurisdictions for a specific medical indication. Where a peptide has a defined regulated medical use, that use is governed by prescription regulations in the relevant jurisdiction and is entirely separate from any research-use supply. Peptovia Research supplies Tesamorelin as a research peptide for in-vitro laboratory research only — no reference to its regulated medical use, dosing or administration is provided or implied.
Researchers interested in the peptide's published pharmacological and clinical literature can access it via PubMed and pharmaceutical development resources; this literature should be evaluated in its clinical-development context, not as guidance for research-supply use.
Analytical considerations
For laboratory work with Tesamorelin, several analytical points are worth noting:
- Identity confirmation. Because Tesamorelin's molecular mass (~5196 Da) lies at the boundary of small peptide and small protein, high-resolution mass spectrometry (ideally ESI-MS on a modern instrument) is used for identity confirmation. See LC-MS peptide testing explained. The N-terminal acyl modification adds a characteristic mass increment that should be observed in the spectrum.
- Purity by HPLC. Reversed-phase HPLC with C18 or C4 columns is standard. Longer peptides typically require optimised gradients to resolve closely related sequence variants. See what is HPLC peptide testing.
- Deletion sequences and truncations. As with any 44-residue synthetic peptide, deletion-sequence impurities are the most common synthesis-related concern; adequate HPLC resolution is essential to detect them.
- Batch documentation. A batch-specific COA disclosing the analytical methods used and the resulting purity and mass values is essential — see how to read a peptide COA.
- Solubility and stability. Tesamorelin is a larger peptide than most in the research-supply landscape; solubility, aggregation and lyophilised-cake integrity are all worth checking against the supplier's documentation.
Further reading
Published pharmaceutical, pharmacological and analytical literature on Tesamorelin is accessible via PubMed and pharmaceutical development resources. For an overview of the analytical framework that applies to peptides of this class, see understanding peptide laboratory testing.
Research Use Only. This profile is an educational overview of Tesamorelin as a research peptide. It does not describe, endorse, or recommend human, veterinary or clinical use, and it does not reference any medical or therapeutic application of the compound as supplied by Peptovia Research. Peptovia Research supplies Tesamorelin strictly for in-vitro laboratory research. No dosing, administration or therapeutic guidance is provided or implied.